A Agilent Technologies Inc.

Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference

(NYSE: A) today announced they will showcase their significantly expanded InfinityLab GPC/SEC Solution at the conference on June 18 – 22, 2023 in Düsseldorf, Germany.

The has become even more comprehensive as it incorporates added value components from recent acquisition of Polymer Standard Service Ltd. (PSS) including a dedicated GPC/SEC Column Thermostat, a Multi-Angle Light Scattering Detector, the GPC/SEC-Ready Kit, and the powerful WinGPC Software into the already existing InfinityLab GPC/SEC Solutions for advanced material characterization.

In combination with Agilent GPC/SEC products like the Bio-GPC/SEC system, High-Temperature GPC system, routine-GPC/SEC software, GPC/SEC columns, standards, and dedicated service offerings this launch of additional products results in the largest one-vendor solution for GPC/SEC.

“We are so pleased to unveil the new GPC/SEC solutions at HPLC,” said Sudharshana Seshadri, vice president of Agilent’s Liquid Chromatography, Mass Spec and Automation divisions. “The combined portfolio of Agilent and PSS delivers a total Agilent solution for the characterization of macromolecules. It enables scientists to update legacy methods, to improve productivity or to address the challenges of characterizing new and innovative high-performance materials for applications within the food, pharmaceutical and biotechnology industries.”

“Our goal at Agilent,” continued Sudharshana Seshadri, “is to deliver the best solutions we can for our customers, considering their current and future needs. Having PSS on board brings unique expertise in serving macromolecular analysis, and combining that with Agilent’s knowledge, and strengths, enables us to address the emerging challenges that customers are facing.”

Also on display, for the first time in Europe at the HPLC 2023 conference, on the Agilent booth #3 will be: offering unique capabilities for complex samples; the which together with the , creates a high-end PAT-solution, and the .

Agilent’s second booth #4 will showcase Agilent’s digital lab solutions. Lab optimization strategies will be articulated around key solutions such as efficient data management systems, electronic laboratory notebooks, scientific asset performance management and digital tools designed to track inventories, manage schedules, aggregate data, provide resource visibility, monitor asset performance & utilization, and integrate with other lab systems.

GPC/SEC

Gel Permeation Chromatography / Size Exclusion Chromatography (GPC/SEC) is an important separation technique for synthetic and natural polymers. GPC/SEC analysis is widely used in the chemical-, food-, pharmaceutical- and biopharmaceutical industry and research in applications to determine the molecular weight and size distribution of macromolecules.

About Agilent Technologies

(NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
12/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch